Searched for
CIPLA RESPIRATORY ASSETS
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Cipla Q3 Results: Net profit plunges 57% YoY to Rs 676 croreCipla Q3 Results: Cipla reported a 57% YoY drop in net profit to Rs 676 crore, impacted by lower gRevlimid sales in North America. Despite ...
- Cipla Q2 Results: Net profit grows 4% YoY to Rs 1,351 crore; revenue rises 8%Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company s...
- Cipla plans 4 major respiratory launches by 2026 after beating Q2 estimates with highest-ever quarterly revenue of Rs 7,500+ crCipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growin...
- Cipla targets $1 bn US revenue in FY27Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in respiratory generics ...
- Cipla faces revenue and margin pressure ahead of Revlimid patent expiryCipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst downgrades. Mar...
- Cipla reports Rs 1049 crore net profit in Q3FY24, on strong US, India salesDrug maker Cipla reported a 33% year-on-year (YoY) jump in net profit to Rs 1049 crore in Q3FY24, led by strong US and India sales momentum.
- Cipla Q3 Results: Profit jumps 32% YoY to Rs 1,056 crore, revenue rises 14%Cipla's Q3 revenue for the quarter grew 13.7% YoY to Rs 6,604 crore, compared to Rs 5,810 crore in the same quarter last year. However, the...
- Cipla Q2 Results: Net profit jumps 45% YoY to Rs 1131 croreCipla's India business that contributes 42% to overall revenue grew 10% YoY to Rs 2817 crore in Q2FY24 with continued momentum across brand...
- Cipla Q2 Results: Profit jumps 43% YoY to Rs 1,131 crore, revenue rises 15%The bottomline was higher than the Rs 1,006 crore which was expected by analysts in an ET Now poll. Cipla's consolidated margin came in at ...
- Cipla Q3 Results: Profit rises 10% YoY to Rs 801 crore but misses estimates; stock hits 4-month lowThe dismal numbers from the drugmaker weighed on the stock, which extended the day’s losses and hit an over 4-month low of Rs 1,021. The sh...
- Buy Cipla, target price Rs 1260: Axis SecuritiesCipla, incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 86522.68 Crore) operating in Pharmaceuticals sector.
- Cipla sticks to 21-22% operating profit guidance for FY23, posts Rs 789 crore profit in Q2Cipla reported a multi-quarter high of $179 million in revenue and 25% YoY growth led by the successful launch of a generic version of the ...
- Why Nithya Balasubramanian is gung-ho on Sun Pharma & Cipla“One gets different types of exposure with Sun Pharma and Cipla. For Sun, the capital allocation into US specialty is now bearing fruit. At...
- Cipla skids 4% on Jan-Mar earnings missThe total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the company reported in the year-ago quar...
- Cipla Q4 Results: Profit falls 12.4% YoY to Rs 362 cr, misses estimatesThe total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the company reported in the year-ago quar...
Load More
